Evaluation of the DAS28 at week 14 or week 22 correlates best with long term attrition to infliximab therapy in rheumatoid arthritis patients

B. Vander Cruyssen; S. Van Looy; B. Wijns; R. Westhovens; P. Durez; F. Van Den Bosch; H. Mielants; L. De Clerck; A. Peretz; M. Malaise; Leon Verbruggen; N. Vastesaeger; A. Geldhof; L. Boullart; F. De Keyser

Evaluation of the DAS28 at week 14 or week 22 correlates best with long term attrition to infliximab therapy in rheumatoid arthritis patients

B. Vander Cruyssen, S. Van Looy, B. Wijns, R. Westhovens, P. Durez, F. Van Den Bosch, H. Mielants, L. De Clerck, A. Peretz, M. Malaise, Leon Verbruggen, N. Vastesaeger, A. Geldhof, L. Boullart, F. De Keyser

Internal Medicine Specializations

Research output: Contribution to journal › Editorial

Abstract

No abstract available

Original language	English
Pages (from-to)	114-115
Number of pages	2
Journal	Ann Rheum Dis
Volume	65
Issue number	2006
Publication status	Published - 2006

Keywords

rheumatoid arthritis patients
DAS28
Rheumatic diseases
infliximab therapy

Access to Document

http://apps.webofknowledge.com.ezproxy.vub.ac.be:2048/full_record.do?product=UA&search_mode=GeneralSearch&qid=2&SID=R28A254@Ni3DJeAmDAM&page=1&doc=3

Cite this

Vander Cruyssen, B., Van Looy, S., Wijns, B., Westhovens, R., Durez, P., Van Den Bosch, F., Mielants, H., De Clerck, L., Peretz, A., Malaise, M., Verbruggen, L., Vastesaeger, N., Geldhof, A., Boullart, L., & De Keyser, F. (2006). Evaluation of the DAS28 at week 14 or week 22 correlates best with long term attrition to infliximab therapy in rheumatoid arthritis patients. Ann Rheum Dis, 65(2006), 114-115. http://apps.webofknowledge.com.ezproxy.vub.ac.be:2048/full_record.do?product=UA&search_mode=GeneralSearch&qid=2&SID=R28A254@Ni3DJeAmDAM&page=1&doc=3

Vander Cruyssen, B. ; Van Looy, S. ; Wijns, B. ; Westhovens, R. ; Durez, P. ; Van Den Bosch, F. ; Mielants, H. ; De Clerck, L. ; Peretz, A. ; Malaise, M. ; Verbruggen, Leon ; Vastesaeger, N. ; Geldhof, A. ; Boullart, L. ; De Keyser, F. / Evaluation of the DAS28 at week 14 or week 22 correlates best with long term attrition to infliximab therapy in rheumatoid arthritis patients. In: Ann Rheum Dis. 2006 ; Vol. 65, No. 2006. pp. 114-115.

@article{538b117d44df4e778690121c7c0f171b,

title = "Evaluation of the DAS28 at week 14 or week 22 correlates best with long term attrition to infliximab therapy in rheumatoid arthritis patients",

abstract = "No abstract available",

keywords = "rheumatoid arthritis patients, DAS28, Rheumatic diseases, infliximab therapy",

author = "{Vander Cruyssen}, B. and {Van Looy}, S. and B. Wijns and R. Westhovens and P. Durez and {Van Den Bosch}, F. and H. Mielants and {De Clerck}, L. and A. Peretz and M. Malaise and Leon Verbruggen and N. Vastesaeger and A. Geldhof and L. Boullart and {De Keyser}, F.",

year = "2006",

language = "English",

volume = "65",

pages = "114--115",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "2006",

}

Vander Cruyssen, B, Van Looy, S, Wijns, B, Westhovens, R, Durez, P, Van Den Bosch, F, Mielants, H, De Clerck, L, Peretz, A, Malaise, M, Verbruggen, L, Vastesaeger, N, Geldhof, A, Boullart, L & De Keyser, F 2006, 'Evaluation of the DAS28 at week 14 or week 22 correlates best with long term attrition to infliximab therapy in rheumatoid arthritis patients', Ann Rheum Dis, vol. 65, no. 2006, pp. 114-115. <http://apps.webofknowledge.com.ezproxy.vub.ac.be:2048/full_record.do?product=UA&search_mode=GeneralSearch&qid=2&SID=R28A254@Ni3DJeAmDAM&page=1&doc=3>

Evaluation of the DAS28 at week 14 or week 22 correlates best with long term attrition to infliximab therapy in rheumatoid arthritis patients. / Vander Cruyssen, B.; Van Looy, S.; Wijns, B.; Westhovens, R.; Durez, P.; Van Den Bosch, F.; Mielants, H.; De Clerck, L.; Peretz, A.; Malaise, M.; Verbruggen, Leon; Vastesaeger, N.; Geldhof, A.; Boullart, L.; De Keyser, F.

In: Ann Rheum Dis, Vol. 65, No. 2006, 2006, p. 114-115.

Research output: Contribution to journal › Editorial

TY - JOUR

T1 - Evaluation of the DAS28 at week 14 or week 22 correlates best with long term attrition to infliximab therapy in rheumatoid arthritis patients

AU - Vander Cruyssen, B.

AU - Van Looy, S.

AU - Wijns, B.

AU - Westhovens, R.

AU - Durez, P.

AU - Van Den Bosch, F.

AU - Mielants, H.

AU - De Clerck, L.

AU - Peretz, A.

AU - Malaise, M.

AU - Verbruggen, Leon

AU - Vastesaeger, N.

AU - Geldhof, A.

AU - Boullart, L.

AU - De Keyser, F.

PY - 2006

Y1 - 2006

N2 - No abstract available

AB - No abstract available

KW - rheumatoid arthritis patients

KW - DAS28

KW - Rheumatic diseases

KW - infliximab therapy

M3 - Editorial

VL - 65

SP - 114

EP - 115

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 2006

ER -

Evaluation of the DAS28 at week 14 or week 22 correlates best with long term attrition to infliximab therapy in rheumatoid arthritis patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this